FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2803604129> ?p ?o ?g. }

• W2803604129 endingPage "563" @default.
• W2803604129 startingPage "553" @default.
• W2803604129 abstract "BackgroundVery late (aged ≥60 years) onset schizophrenia-like psychosis occurs frequently but no placebo-controlled, randomised trials have assessed the efficacy and risks of antipsychotic treatment. We investigated whether low-dose amisulpride (100 mg daily) is superior to placebo in reducing psychosis symptoms over 12 weeks and whether any benefit is maintained by continuing treatment after 12 weeks.MethodsThe ATLAS double-blind controlled trial enrolled participants from 25 old age psychiatry services in the UK. Eligible participants (ie, those with a diagnosis of very late-onset schizophrenia-like psychosis and a Brief Psychiatric Rating Scale [BPRS] score of ≥30, without cognitive impairment) were randomly assigned (1:1:1) to one of three groups in a two-stage trial: amisulpride in stage 1 and 2 (group A), amisulpride then placebo (group B), or placebo then amisulpride (group C). Treatment (100 mg oral amisulpride daily vs placebo) was given for 12 weeks in stage 1 and, initially, 24 weeks then reduced to 12 weeks in stage 2. Participants, investigators, and outcome assessors were masked to treatment allocation. Primary outcomes were psychosis symptoms assessed by the BPRS at 4, 12, and 24, or 36 weeks, and trial treatment discontinuation for non-efficacy. The primary, secondary, and safety endpoints were all analysed in participants given at least one dose of study treatment in modified intention-to-treat analyses. This study is registered with EudraCT, number 2010-022184-35, and ISRCTN, number ISRCTN45593573.FindingsBetween Sept 27, 2012, and June 28, 2016, we recruited 101 participants. 92 (91%) of 101 participants took trial medication, of whom 59 (64%) completed stage 1 and 34 (58%) of these 59 participants completed stage 2 treatment. Despite suboptimal compliance, improvements in BPRS scores at 12 weeks were 7·7 points (95% CI 3·8–11·5, p=0·0002) greater with amisulpride (mean 11·9 points [SE 1·3]) than with placebo (4·2 points [1·0]). In stage 2, BPRS scores improved by a mean of 1·1 points (1·6) from 12 weeks to the final assessment in those who continued amisulpride but deteriorated by 5·2 points (2·0) in those who switched from amisulpride to placebo (difference 6·3 points [95% CI 0·9–11·7], p=0·024). Fewer participants who were allocated amisulpride than placebo stopped treatment because of non-efficacy in stage 1 (p=0·010) and stage 2 (p=0·031). Serious adverse events were reported more frequently in the amisulpride group than in the placebo group in stage 1 (p=0·057) and stage 2 (p=0·19). The most common serious adverse events were infection (five patients in the amisulpride group, three in the placebo group) and extrapyramidal side-effects (three patients in the amisulpride group, none in the placebo group). Five patients died during the study, one from a gastric ulcer bleed before treatment started (group B), two while taking stage 2 treatment (one in group A and one in group C), and two who stopped trial treatment in stage 1 and died many weeks later (one in group B and one in group C). No deaths were related to treatment.InterpretationLow-dose amisulpride is effective and well tolerated as a treatment for very late-onset schizophrenia-like psychosis, with benefits maintained by prolonging treatment.FundingUK National Institute for Health Research." @default.
• W2803604129 created "2018-06-01" @default.
• W2803604129 creator A5005887947 @default.
• W2803604129 creator A5007323180 @default.
• W2803604129 creator A5007971870 @default.
• W2803604129 creator A5010649242 @default.
• W2803604129 creator A5011241516 @default.
• W2803604129 creator A5017010556 @default.
• W2803604129 creator A5022859960 @default.
• W2803604129 creator A5024001082 @default.
• W2803604129 creator A5029882530 @default.
• W2803604129 creator A5031675404 @default.
• W2803604129 creator A5033361414 @default.
• W2803604129 creator A5035979012 @default.
• W2803604129 creator A5038600511 @default.
• W2803604129 creator A5038642407 @default.
• W2803604129 creator A5041409152 @default.
• W2803604129 creator A5043071365 @default.
• W2803604129 creator A5054173992 @default.
• W2803604129 creator A5065631542 @default.
• W2803604129 creator A5067131273 @default.
• W2803604129 creator A5068994533 @default.
• W2803604129 creator A5073010113 @default.
• W2803604129 creator A5082498457 @default.
• W2803604129 creator A5083056862 @default.
• W2803604129 creator A5084818858 @default.
• W2803604129 creator A5087336618 @default.
• W2803604129 date "2018-07-01" @default.
• W2803604129 modified "2023-10-16" @default.
• W2803604129 title "Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial" @default.
• W2803604129 cites W1557468140 @default.
• W2803604129 cites W1956625913 @default.
• W2803604129 cites W1966046188 @default.
• W2803604129 cites W1977733462 @default.
• W2803604129 cites W1978211228 @default.
• W2803604129 cites W2021186654 @default.
• W2803604129 cites W2024703744 @default.
• W2803604129 cites W2033134576 @default.
• W2803604129 cites W2038799193 @default.
• W2803604129 cites W2044006023 @default.
• W2803604129 cites W2045109649 @default.
• W2803604129 cites W2057888471 @default.
• W2803604129 cites W2072303299 @default.
• W2803604129 cites W2081342992 @default.
• W2803604129 cites W2095986823 @default.
• W2803604129 cites W2113886123 @default.
• W2803604129 cites W2115117600 @default.
• W2803604129 cites W2131273350 @default.
• W2803604129 cites W2132871355 @default.
• W2803604129 cites W2138418037 @default.
• W2803604129 cites W2141438777 @default.
• W2803604129 cites W2165379748 @default.
• W2803604129 cites W2598146495 @default.
• W2803604129 cites W4379093136 @default.
• W2803604129 doi "https://doi.org/10.1016/s2215-0366(18)30141-x" @default.
• W2803604129 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6015223" @default.
• W2803604129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29880238" @default.
• W2803604129 hasPublicationYear "2018" @default.
• W2803604129 type Work @default.
• W2803604129 sameAs 2803604129 @default.
• W2803604129 citedByCount "42" @default.
• W2803604129 countsByYear W28036041292018 @default.
• W2803604129 countsByYear W28036041292019 @default.
• W2803604129 countsByYear W28036041292020 @default.
• W2803604129 countsByYear W28036041292021 @default.
• W2803604129 countsByYear W28036041292022 @default.
• W2803604129 countsByYear W28036041292023 @default.
• W2803604129 crossrefType "journal-article" @default.
• W2803604129 hasAuthorship W2803604129A5005887947 @default.
• W2803604129 hasAuthorship W2803604129A5007323180 @default.
• W2803604129 hasAuthorship W2803604129A5007971870 @default.
• W2803604129 hasAuthorship W2803604129A5010649242 @default.
• W2803604129 hasAuthorship W2803604129A5011241516 @default.
• W2803604129 hasAuthorship W2803604129A5017010556 @default.
• W2803604129 hasAuthorship W2803604129A5022859960 @default.
• W2803604129 hasAuthorship W2803604129A5024001082 @default.
• W2803604129 hasAuthorship W2803604129A5029882530 @default.
• W2803604129 hasAuthorship W2803604129A5031675404 @default.
• W2803604129 hasAuthorship W2803604129A5033361414 @default.
• W2803604129 hasAuthorship W2803604129A5035979012 @default.
• W2803604129 hasAuthorship W2803604129A5038600511 @default.
• W2803604129 hasAuthorship W2803604129A5038642407 @default.
• W2803604129 hasAuthorship W2803604129A5041409152 @default.
• W2803604129 hasAuthorship W2803604129A5043071365 @default.
• W2803604129 hasAuthorship W2803604129A5054173992 @default.
• W2803604129 hasAuthorship W2803604129A5065631542 @default.
• W2803604129 hasAuthorship W2803604129A5067131273 @default.
• W2803604129 hasAuthorship W2803604129A5068994533 @default.
• W2803604129 hasAuthorship W2803604129A5073010113 @default.
• W2803604129 hasAuthorship W2803604129A5082498457 @default.
• W2803604129 hasAuthorship W2803604129A5083056862 @default.
• W2803604129 hasAuthorship W2803604129A5084818858 @default.
• W2803604129 hasAuthorship W2803604129A5087336618 @default.
• W2803604129 hasBestOaLocation W28036041291 @default.
• W2803604129 hasConcept C118552586 @default.
• W2803604129 hasConcept C126322002 @default.
• W2803604129 hasConcept C142724271 @default.
• W2803604129 hasConcept C15744967 @default.

• next